Tenet Healthcare Corporation (THC) Stock Analysis 2026

HealthcareMedical Care Facilities
$270.57
as of 2026-10-29
+41.2% (52-week)50D MA $232.91  |  200D MA $207.22

BriMind AI Score

Proprietary
66
Moderate
Price CAGR
28.7%
1Y Return
+27.6%
Analyst Upside
+6.2%
Rev Growth
6.8%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$302.82+11.9% potential
Bear Case
$232.29
Bull Case
$357.22
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($310.77) and Wall Street's consensus target ($294.86).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

THC Revenue & Profitability Breakdown

This chart shows how THC's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$21.81B
Cost of Revenue
-$12.72B
Gross Profit
$9.09B41.7% margin
Operating Expenses
-$5.13B
Operating Income
$3.96B18.2% margin
Tax & Other
-$1.72B
Net Income
$2.24B10.3% margin
Gross Margin
41.7%
Operating Margin
18.2%
Net Margin
10.3%

Key Financial Metrics

Tenet Healthcare Corporation trades at a trailing P/E of 9.99x, generates $2.25B in free cash flow, runs a debt/equity ratio of 152.28, and converts shareholder equity into profit at a 37.3% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$20.82B
P/E (Trailing)
9.99
P/E (Forward)
12.26
PEG Ratio
1.84
Price / Book
4.47
Revenue
$21.81B
Revenue Growth
6.8%
Earnings Growth
213.4%
EPS (Trailing)
$25.87
EPS (Forward)
$21.08
Gross Margin
41.7%
Operating Margin
18.2%
Net Margin
10.3%
Return on Equity
37.3%
Return on Assets
8.3%
Free Cash Flow
$2.25B
Debt / Equity
152.28
Current Ratio
1.41
Quick Ratio
1.15
Beta
1.23
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
1.0%
Inst. Ownership
102.4%
Short % Float
3.7%
Book Value / Share
$57.86

Wall Street Analyst Consensus

Wall Street analysts covering Tenet Healthcare Corporation currently haven't converged on a clear consensus rating, with a mean 12-month price target of $285.10 (+5.4% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$285.10+5.4% upside

Intrinsic Value Estimates for THC

We use 3 valuation models to estimate THC's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Graham Number
$183.51
-32.2% vs current
Benjamin Graham's formula: √(22.5 × EPS × Book Value). A conservative floor value for stable, profitable companies. Works best for value-oriented businesses.
P/E Based (15× trailing)
$388.05
+43.4% vs current
Multiplies trailing 12-month earnings per share by 15× — a historically average P/E for the stock market. Simple but ignores future growth.
P/E Based (15× forward)
$316.23
+16.9% vs current
Multiplies next year's estimated earnings per share by 15×. More forward-looking; useful for high-growth companies where current earnings understate potential.
Fair Value Range
$183.51 – $388.05
Average Estimate
$295.93
Potential Upside
9.4%

Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Technical Price Signals

THC is currently in a golden cross pattern, trading above its 50-day average of $232.91 and above its 200-day average of $207.22. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$270.57
50-Day MA
$232.91
▲ Price above
200-Day MA
$207.22
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Compare THC with Peers

HCA vs THCHCA Healthcare vs Tenet Healthcare — Which Hospital Sto
CYH vs THCCommunity Health Systems vs Tenet Healthcare — Rural vs

Further Reading

Research and guides that put THC’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

FundamentalsHow to Read a 10-K Annual Report: Complete Investor GuideFundamentals10 Stock Analysis Tools Every Investor Should Know AboutFundamentalsFactor Investing Guide 2026: Value, Momentum, Quality & Low Volatility — Which Factors Work?Risk ManagementHow to Build Your First Investment Portfolio: Risk Tolerance, Asset Allocation & Your First 5 Funds

More Healthcare Stock Analysis

In-depth reports on companies operating alongside THC — business models, bull and bear cases, and the metrics that matter.

HCAHCA Healthcare, Inc.Medical Care FacilitiesCVSCVS Health CorporationHealthcare PlansDXCMDexCom, Inc.Medical DevicesSTESTERIS plcMedical DevicesABBVAbbVie Inc.Drug Manufacturers - GeneralVRTXVertex Pharmaceuticals IncorporatedBiotechnologyZBHZimmer Biomet Holdings, Inc.Medical DevicesEWEdwards Lifesciences CorporationMedical Devices

Unlock the Full THC Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis